molecules of the month

An oral, brain penetrant EGFR mutant inhibitor with exquisite selectivity, a drug that was originally developed from a brain cholesterol metabolite, and a muscarinic antagonist and β2 agonist that was developed using soft drug design are some examples of this month's MOTM.

In the slide deck, you'll also find a drug utilizing an N-oxide motif and a drug optimized to overcome aldehyde oxidase metabolism.

Check out the ten molecule minireviews in the slide deck which covers:

• Where are all of the Molecules of the Month in clinical development?
• What's known about differentiation from previous molecules?
• Where did the starting points come from?
• Industry context, mechanism of action details, and more…